Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onvansertib in CMML and MDS/MPN Overlap Neoplasms
NCT05549661Phase 1Recruiting
- Sponsor
- Mayo Clinic
- Start
- Apr 2023
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of onvansertib in chronic myelomonocytic leukemia (CMML) and myelodysplastic/myeloproliferative neoplasm (MDS/MPN), sponsored by Mayo Clinic. Primary endpoint: Incidence of adverse events up to 4 years. Started Apr 2023; status: recruiting.
02
Drugs
onvansertib
03
Conditions
chronic myelomonocytic leukemia (CMML)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on NCT05549661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05549661.